Company Filing History:
Years Active: 2011
Title: Keisuke Nakajou: Innovator in Glycosylated Albumin Technology
Introduction
Keisuke Nakajou is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of biochemistry, particularly in the development of glycosylated albumin as a drug carrier. His innovative approach has the potential to enhance drug delivery systems targeting the liver.
Latest Patents
Keisuke Nakajou holds a patent for a "Sugar chain-containing albumin, production method thereof and use thereof." This invention focuses on glycosylated albumin as a drug carrier for a drug delivery system (DDS) that specifically targets the liver, particularly Kupffer's cells. The method involves mutating a DNA sequence encoding albumin to create a mutant albumin that allows for glycosylation modification. This process includes introducing an expression vector containing the mutant DNA into a host eukaryotic cell, culturing the transformant, and recovering the glycosylated albumin protein from the culture.
Career Highlights
Keisuke Nakajou is associated with Nipro Corporation, where he continues to advance his research and development efforts. His work has garnered attention for its potential applications in medical therapies and drug delivery systems.
Collaborations
Keisuke collaborates with notable colleagues, including Naohisa Katayama and Toshiya Kai. Their combined expertise contributes to the innovative projects at Nipro Corporation.
Conclusion
Keisuke Nakajou's contributions to the field of glycosylated albumin technology highlight his role as a key innovator in biochemistry. His patent and ongoing research promise to impact drug delivery systems significantly.